Table 1.
Clinicopathologic Features of Primary Prostatic Adenocarcinoma Patients Before and After Radiation
| Pre-radiation biopsy
|
Radiation (Gy) |
Post-radiation biopsy
|
Metastasis | Follow up |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Age (years) |
PSA (ng/ml) |
Tumor stage |
Prognostic group |
Gleason score |
CD44 (%) |
CD133 (%) |
Age (years) |
PSA (ng/ml) |
CD44 (%) |
CD133 (%) |
|||
| 1 | 66 | 10.4 | T2c | IIB | 7 | 0 | 0 | 69 | 71 | 9.1 | 0 | 0 | None | 13 Mo, AWD* |
| 2 | 61 | 43.5 | T3 | III | 9 | 0 | 0 | 76 | 64 | 7.5 | 0 | 0 | None | 20 Mo, AWD* |
| 3 | 57 | 21.6 | T2b | IIB | 7 | 0 | 0 | 65 | 60 | 3.2 | 2 | 0 | None | 5 Mo, AWOD* |
| 4 | 78 | 9.8 | T2c | IIB | 7 | 0 | 0 | 60 | 82 | 17.2 | 10 | 0 | Bone | 36 Mo, AWD* |
| 5 | 63 | 14.5 | T4 | IV | 8 | 0 | 0 | 70 | 67 | 3.1 | 35 | 0 | Bone, liver, lung | 6 Mo, DOD* |
Abbreviations: PSA, prostate specific antigen; AWD, alive with disease; AWOD, alive without disease; DOD, dead of disease.